Eli Lilly has welcomed Carolyn R. Bertozzi, Ph.D., as a new member, of its board, starting on February 10, 2017, joining two committees of the board.
As a member of Lilly’s board, she will serve on the Science and Technology and Public Policy and Compliance Committees of the board.
She is a Professor of Chemistry and Professor of Chemical & Systems Biology and Radiology (by courtesy) at Stanford University, and an Investigator of the Howard Hughes Medical Institute.
John C. Lechleiter, chairman of the board of directors, said: “Professor Bertozzi, with her broad scientific expertise and solid record of accomplishment, along with her understanding of the biopharmaceutical industry, will contribute greatly to our board and our company as we seek to advance Lilly’s pipeline of potential new medicines to benefit patients and our other key stakeholders.”